Practical Investment Analysis for the New Energy EconomyAI Just Fired Your DoctorNot long ago, a patient showed up at Beth Israel Deaconess Medical Center in Boston with a pulmonary embolism. Doctors used the standard protocol to begin treating the patient. All was great at first, especially as the patient started to recover. Unfortunately, it wasn’t long before the symptoms worsened. The medical team suspected the medication wasn't working. Maybe the dosage needed adjustment, or perhaps the clot was resisting treatment. That’s when AI stepped in… And when OpenAI's latest reasoning model scanned the patient's electronic health records, it noticed something the doctors missed. You see, it turns out that the patient had a history of lupus — an autoimmune condition that can cause heart inflammation. The AI's theory was pretty simple. It didn’t think the blood clot medication was failing. Instead, the supposed culprit might’ve been undiagnosed heart inflammation from the lupus. As you can probably guess by now, the AI was spot-on. However, this wasn't some controlled lab experiment or fictional fantasy. We’re talking about a real patient with real medical records, and actual doctors making real-time decisions in an emergency room. Last week, researchers at Harvard Medical School published the results in Science. When the OpenAI's model was tested against experienced physicians across multiple cases, AI didn’t just match the doctors’ performance, it consistently outperformed them. And it did so with nothing but electronic health records — the same limited information the doctors had at the time. Welcome to the new reality of AI-driven medicine. And you can bet it’s far better at getting results than we are.
AI Is STEALING From You It’s time to delete ALL of your social media accounts. Why? Because AI firms are downloading every part of your digital identity to train AI models like ChatGPT WITHOUT your permission or any compensation. Luckily, I’ve found a government-backed income stream that could pay you up to $41,430 a year in “AI equity checks.” Best of all, it takes only five minutes and as little as $10 to get started! Follow these three simple steps to receive your first check. AI Just Fired Your Doctor Look, that Harvard study is just the visible tip of what's happening in pharmaceutical R&D right now. You and I both know that drug discovery has always been brutally slow and expensive. Remember, it took well over a decade for a company to take a drug candidate from target identification to FDA approval. Oh, and did I mention the fact that the price tag attached to this development exceeded $2.6 billion PER DRUG. Of course, that doesn’t factor in the ~90% clinical trial failure rate that's been stuck at that level for decades. The interesting thing here is that the bottleneck ISN’T funding. The difficulty is the sheer amount of data that needs to be taken into account — the chemical space of potential drug compounds alone is estimated at 10⁶⁰ molecules. For the record, that's more combinations than you can explore with traditional methods in a thousand lifetimes. That’s how AI entirely changes the math! You see, instead of testing molecules one at a time in labs, AI models can simulate millions of interactions computationally. They predict which compounds will bind to target proteins, calculate toxicity, and model how drugs will behave in the body — all before synthesizing a single physical sample. Granted, the companies doing this aren't running pilots anymore. Rather, they're building the AI platforms that are reshaping the entire drug development pipeline. If you recall earlier this year, NVIDIA and Eli Lilly announced a $1 billion joint investment to create an AI co-innovation lab in San Francisco. This isn’t some minor research partnership, dear reader. It’s a fully operational facility where NVIDIA's AI engineers work side-by-side with Lilly's biologists and chemists. And the infrastructure is built on NVIDIA's BioNeMo platform — a generative AI framework specifically designed for drug discovery. So what’s the goal here? Well, the plan is to train foundation models for biology and chemistry that can identify, optimize, and validate new molecules with speed and accuracy that didn't exist five years ago. Then not too long ago, Roche deployed over 3,500 NVIDIA Blackwell GPUs across its global AI infrastructure. That's the largest announced GPU footprint available to any pharmaceutical company. The system spans facilities in the U.S. and Europe, embedded across diagnostics and therapeutics development. The speed gains are quite real, and what used to take months of lab work now happens in days or weeks computationally. NVIDIA's BioNeMo platform is becoming the operating system for this new world by providing the development platform to generate and process data, train models, and deploy them into production workflows. Right now, the industry's entering what’s considered the "builder phase." Organizations aren't just running AI pilots. They're reshaping their data environments and organizational structures to make AI the default part of R&D operations. And you know what? It's working. The first AI-designed drugs are advancing through clinical trials. Some are already in Phase III — the final stage before regulatory approval. If those trials succeed, they'll validate that AI won’t simply accelerate timelines, but also improve outcomes. AI Didn’t Assist Your Doctor, It Beat Them Now here’s the part that the market's missing… Everyone's watching Big Pharma steal headlines anytime new milestones are reached. But the real leverage is in the platforms driving this entire shift. Sure, NVIDIA's the obvious one. Every major pharma company scaling AI is buying NVIDIA GPUs. Lilly's $1 billion lab is built on NVIDIA infrastructure. Meanwhile, Roche's 3,500 GPUs use NVIDIA Blackwell chips. But NVIDIA's not just selling hardware. It's providing the software stack — BioNeMo, NeMo framework, Isaac Sim for robotics — that lets pharma companies actually deploy AI at scale. And every time a new drug discovery project spins up, it’s going to need more compute power and more GPUSs. Currently, the R&D spending in pharma is estimated at $300 billion annually. However, we both know that AI has the potential to cut that dramatically while improving success rates — even capturing a fraction of that spend represents a massive addressable market for the companies building the picks and shovels. Right now, tomorrow’s pharmaceutical industry is being rebuilt from the ground up. And the companies providing the foundation? Well, that’s precisely where you’ll find the leverage you’re looking for — you just have to know where to look. Until next time,
Keith Kohl A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing's Energy Investor and Technology and Opportunity. For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology. Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.
|
AI Just Fired Your Doctor
By -
May 08, 2026
0
Check us out on YouTube!
Post a Comment
0Comments